niman wrote:
Collection date
Date: 2009-07-15
Location: Europe / Sweden / Stockholms Lan
Host: Human
Additional host information Patient treated in ECMO
Host properties: N/A
Patient age: 22 Y
Gender: M
Zip code:
Patient status: Recovered
Last vaccinated: 0
Outbreak:
Treatment: unknown
In-vivo pathogenicity test:
Specimen source: Nasopharyngeal
Domestic status:
Health status:
Vaccinated:
Specimen source:
Strain or commercial product name used for vaccination:
In-vivo pathogenicity test:
Supplementary data
Originating Laboratory
provider of clinical specimen(s)
and/or virus isolate(s) [Sweden, Solna] Swedish Institute for Infectious Disease Control
Address: Department of Virology Nobelsvÿg 18 S-171 82 Solna Sweden
Sample ID given by the sample provider A/Stockholm/48/2009
Dr. Niman,
Is this from the new sequence from Sweden that was just released? If so, how was the D225G found in the nasopharyngeal sample, when it has been commented (I think by you) that D225G usually is found deep in the lungs and was not being found higher up in the respiratory tract. Does this mean that the mutated virus is moving higher up in the lungs? I am a little confused. Any clarification would be greatly appreciated.
Thanks!
Login
Register
FAQ
Search
